StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO – Free Report) in a research report report published on Wednesday. The firm issued a sell rating on the medical device company’s stock.
NeuroMetrix Price Performance
Shares of NASDAQ:NURO opened at $4.34 on Wednesday. The stock’s 50 day moving average price is $4.04 and its 200 day moving average price is $3.84. NeuroMetrix has a 12 month low of $2.66 and a 12 month high of $4.73.
NeuroMetrix (NASDAQ:NURO – Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share for the quarter. The firm had revenue of $0.59 million during the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. During the same period last year, the business posted ($1.66) EPS.
NeuroMetrix Company Profile
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.
See Also
- Five stocks we like better than NeuroMetrix
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- How to Read Stock Charts for Beginners
- Williams-Sonoma Stock: Buy It and Never Let It Go
- High Flyers: 3 Natural Gas Stocks for March 2022
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.